On October 10, 2023 XNK Therapeutics AB ("XNK") reported that it has applied for and been granted funding by Sweden’s innovation agency Vinnova (Press release, XNK Therapeutics, OCT 10, 2023, View Source [SID1234635830]). The grant consists of SME support through the Competence Center for Next-generation NK Cell-based Cancer Immunotherapy (NextGenNK). The competence center is coordinated by the Karolinska Institutet and XNK has been a member since the center’s inception in 2020. The funding amounts to up to 1.7 million SEK over two years and will be used in a specific preclinical program in XNK’s project portfolio.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!